Polysaccharide K and Coriolus versicolor Extracts for Lung Cancer

Integrative Cancer Therapies - Tập 14 Số 3 - Trang 201-211 - 2015
Heidi Fritz1, Deborah Kennedy1,2, Mami Ishii1, Dean Fergusson3, Rochelle Fernandes1,2, Kieran Cooley1,2, Dugald Seely1,3,4
1Canadian College of Naturopathic Medicine, Toronto, Ontario, Canada
2The University of Toronto, Toronto, Ontario, Canada
3Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
4Ottawa Integrative Cancer Centre, Ottawa, Ontario, Canada

Tóm tắt

Background. Polysaccharide K, also known as PSK or Krestin, is derived from the Coriolus versicolor mushroom and is widely used in Japan as an adjuvant immunotherapy for a variety of cancer including lung cancer. Despite reported benefits, there has been no English language synthesis of PSK for lung cancer. To address this knowledge gap, we conducted a systematic review of PSK for the treatment of lung cancer. Methods. We searched PubMed, EMBASE, CINAHL, the Cochrane Library, AltHealth Watch, and the Library of Science and Technology from inception to August 2014 for clinical and preclinical evidence pertaining to the safety and efficacy of PSK or other Coriolus versicolor extracts for lung cancer. Results. Thirty-one reports of 28 studies were included for full review and analysis. Six studies were randomized controlled trials, 5 were nonrandomized controlled trials, and 17 were preclinical studies. Nine of the reports were Japanese language publications. Fifteen of 17 preclinical studies supported anticancer effects for PSK through immunomodulation and potentiation of immune surveillance, as well as through direct tumor inhibiting actions in vivo that resulted in reduced tumor growth and antimetastatic effects. Nonrandomized controlled trials showed improvement of various survival measures including median survival and 1-, 2-, and 5-year survival. Randomized controlled trials showed benefits on a range of endpoints, including immune parameters and hematological function, performance status and body weight, tumor-related symptoms such as fatigue and anorexia, as well as survival. Although there were conflicting results for impact on some of the tumor-related symptoms and median survival, overall most randomized controlled trials supported a positive impact for PSK on these endpoints. PSK was safely administered following and in conjunction with standard radiation and chemotherapy. Conclusions. PSK may improve immune function, reduce tumor-associated symptoms, and extend survival in lung cancer patients. Larger, more rigorous randomized controlled trials for PSK in lung cancer patients are warranted.

Từ khóa


Tài liệu tham khảo

10.3322/caac.20073

10.1159/000262477

Kidd PM, 2000, Altern Med Rev, 5, 4

Fisher M, 2002, Anticancer Res, 22, 1737

10.1002/1097-0142(19921115)70:10<2475::AID-CNCR2820701014>3.0.CO;2-P

10.1007/BF01740932

10.1007/BF02468887

10.1016/S0306-3623(97)00076-1

10.7326/0003-4819-134-8-200104170-00012

10.1016/j.jclinepi.2005.12.020

Ottawa Hospital Research Institute. The Newcastle-Ottawa Scale (NOS). http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed 24 September 2010.

10.1089/107555303321222991

10.1016/0197-2456(95)00134-4

Liu J, 1993, PSP International Symposium, 1993, 183

Liu J, Advanced Research in PSP, 1999, 295

Hayakawa K, 1997, Cancer Detect Prev, 21, 71

Hayakawa K, 1993, Anticancer Res, 13, 1815

Hiyoshi Y, 1981, J Japan Soc Cancer Ther, 16, 1384

Ikeda T, 1986, Jpn J Cancer Chemother, 13, 1044

Katoh R, 1998, Biotherapy, 12, 667

Katoh R, 1998, Oncol Rep, 5, 103

10.2482/haigan.30.903

Matsushima T, 1980, Jpn J Cancer Chemother, 7, 1998

Nishiwaki Y, 1990, Jpn J Cancer Chemother, 17, 131

Ogawa Y, 1981, J Japan Soc Cancer Ther, 16, 713

Ogawa Y, 1982, Jpn J Clin Radiol, 27, 451

Ogawa Y, 1982, Jpn J Clin Radiol, 27, 1445

10.1053/rmed.2003.1490

Hattori T, 1982, Gan, 73, 132

10.1007/BF02469383

10.1023/A:1008070025561

Ishihara Y, 1998, In Vivo, 12, 175

10.1016/S0306-4530(99)00023-2

Ito H, 1976, Mie Med J, 26, 51

10.1186/1471-2407-8-78

10.1111/j.1349-7006.1991.tb01941.x

10.1016/0165-2478(92)90121-4

Katoh R, 2007, Cell Mol Immunol, 4, 295

Matsunaga K, 2000, Cancer Epidemiol Biomarkers Prev, 9, 1313

Matsunaga K, 1996, Invasion Metastasis, 16, 27

10.1159/000226989

10.1159/000227353

10.1093/jnci/56.1.185

10.1007/BF01756187

10.1016/S0162-3109(98)00045-9

10.1007/s00262-008-0498-1

10.1016/1357-2725(95)00157-3

10.1007/s00595-011-0075-7

10.1016/0305-7372(84)90005-7

10.1016/0192-0561(88)90128-2

10.1177/0091270002042009004

Kondo M, Basic Mechanisms and Clinical Treatment of Tumor Metastasis, 1985, 623

Thông tin
Thông tin xuất bản

Integrative Cancer Therapies

Tập 14 Số 3

201-211

Thông tin tác giả